Spyryx Biosciences to Present at the Needham Healthcare Conference
Tuesday, April 4, 2017 New York, NY
Durham, North Carolina – March 29, 2017. Spyryx Biosciences, a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, announced today that John Taylor, President and CEO, will present at the Needham Healthcare Conference on Tuesday, April 4, 2017, at 2:20 p.m. ET in at the Westin Grand Central Hotel in New York, NY.
Mr. Taylor will provide an update on the Company’s corporate progress, clinical activities, and anticipated milestones for SPX-101, its lead candidate in development for the treatment of cystic fibrosis (CF), including successful Phase 1 results and plans for the upcoming clinical trials in CF patients.
SPX-101 is an inhaled peptide with a novel mechanism for regulating epithelial sodium channels in the airway. The drug is designed to increase airway hydration and promote mucociliary clearance, which is dysfunctional in CF. The mechanism of action of SPX-101 is independent of the genetic mutations that cause CF, which makes it a potential therapy for all CF patients.